Definition:Genetic testing moratorium
🧬 Genetic testing moratorium is a voluntary or legislated restriction that prevents insurers from requiring applicants to undergo genetic tests, or from using the results of previously taken genetic tests, when underwriting life, health, critical illness, or income protection insurance. These moratoriums exist at the intersection of insurance risk selection and public health ethics: as genetic science has advanced rapidly, enabling individuals to learn their predisposition to conditions like Huntington's disease, BRCA-related cancers, or hereditary cardiac conditions, governments and industry bodies have grappled with whether insurers should be permitted to factor such information into pricing and acceptance decisions. The moratorium concept recognizes that unrestricted use of genetic data could deter people from pursuing beneficial testing, create an uninsurable genetic underclass, and undermine public health initiatives.
⚙️ The most prominent example is the United Kingdom's Code on Genetic Testing and Insurance, an agreement between the UK government and the Association of British Insurers under which insurers voluntarily refrain from requesting or using predictive genetic test results for most insurance products below certain financial thresholds. Under this code, only Huntington's disease test results may be considered, and only for life insurance policies above a specified sum assured. In other jurisdictions, the approach varies significantly. Canada enacted the Genetic Non-Discrimination Act in 2017, making it a criminal offense for insurers to require genetic test results. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits use of genetic information in health insurance underwriting but notably does not extend to life, disability, or long-term care insurance, leaving a patchwork of state-level protections. Australia's Financial Services Council maintains a moratorium with defined limits. In contrast, several Asian markets have yet to adopt formal restrictions, though regulatory discussion is intensifying as genetic testing becomes more accessible through direct-to-consumer services.
💡 For the insurance industry, genetic testing moratoriums create a deliberate asymmetry of information: applicants may possess knowledge about their own genetic risk that insurers are barred from accessing. This introduces adverse selection concerns, as individuals who discover elevated genetic risk may be more motivated to purchase coverage at standard rates, potentially skewing the risk pool. Actuaries and underwriters must therefore model the financial impact of this information gap and build appropriate margins into pricing — a challenge that grows as genetic testing becomes cheaper and more widespread. Reinsurers supporting life and health portfolios closely monitor developments in genetic science and moratorium policy, as shifts in either domain can alter claims experience materially. The moratorium framework represents a social contract: insurers accept some degree of adverse selection risk in exchange for public trust and the broader societal benefit of encouraging genetic research and preventive medicine. As genomic data becomes increasingly central to healthcare, the boundaries of this contract will continue to be tested and renegotiated across jurisdictions.
Related concepts: